Consultancy providing strategy and business development services to life science investors and companies
• Founder and Chief Executive Officer
• Advises life science VCs on biotech investment opportunities, due diligence and company valuations
• Supports biotech and diagnostics companies in fundraising and partnering and in the development and execution of winning plans and strategies.

Part time supervising business agreement

Antibody-Drug Conjugate (ADC) biotech with first-in-class ADC payload and IND-stage portfolio. HQ and R&D in Singapore and clinical operations in Boston, US.
● Chief Business Officer Led Axcynsis' $40M series A fundraising and comprehensive partnering efforts with the goal to establish the company as a leading ADC platform company globally and transform the future of chemotherapy.

Columbia University spinout pioneering neuroprotection using first-in-class acute (IV) omega-3 diglyceride therapeutics for both rare diseases and some of the world's largest and most costly unmet medical needs.
● Chief Executive Officer Spearheaded the development of the Columbia University spinout to becoming an established early stage biotech supported by a solid business case, a board and highly esteemed advisors and partners. Initiated strategic redirection to an orphan lead indication to minimize cost and time to critical phase 2 proof-of-concept milestone to mitigate the high-risk of a first-in-class neuroprotective therapy and address investor concerns. Headed very comprehensive series A fundraising and partnering efforts globally and successful efforts to secure non-dilutive funding. Led the outsourcing of process development, pilot scale manufacturing and large animal studies, and was instrumental in the design of IND-enabling and clinical studies and preparations for an FDA

Headed strategy, business and organizational development from the company's inception to drive evolution toward clinical-stage, trans-Atlantic orphan drug company and exit for the company's three institutional investors.
• Delivered investor exit and potential 10x return on investment through sales of all of Prophylix's assets to US orphan drug specialist Rallybio (RLYB), leading pitching, due diligence and negotiations to closing.
• Initiated and led extensive C-level partnership and M&A negotiations worth 8- to 9-figure dollars with three $200-1,000M public companies, and worked with leading transaction advisor on business development.
• Led comprehensive HEOR project in collaboration with Creativ Ceutical (now Inizio) and independent expert advisors, generating detailed US and UK cost-effectiveness, budget impact and pricing data
• Led preparations for, and execution of, very successful in-person meetings with FDA and EMA, and led the preparation of approved FDA Rare Pediatric D

Consultancy providing business development services to biotech & life science companies and institutions
Senior Consultant (part-time 2012 – 2013) Formulated and executed biotech strategy and business development projects for clients, with focus on scientific/technical due diligence, market and competitive research, financial analyses, valuations, out-licensing, and deal structuring. Advised investment firms on potential and value of portfolio companies, and on portfolio strategy.
• Drove critical assessment of medical device company—including technology platform, patent portfolio, and market potential—that led to complete change in business mission, direction, and management.
• Valued 5 early-stage biotech companies and recommended one for priority investment, which was listed on Nasdaq within 3 years (whereas the others were later closed).
• Coordinated writing of successful EU grant application for €6M for Prophylix and consortium of 10 partners.
• Authored successful orphan dr